Success Metrics

Clinical Success Rate

77.0%

Based on 141 completed trials

Completion Rate

77%(141/183)

Active Trials

23(10%)

Results Posted

85%(120 trials)

Terminated

42(19%)

Phase Distribution

Ph phase_2

33%

Ph phase_3

Ph not_applicable

Ph early_phase_1

Ph phase_1

138

62%

Phase Distribution

139

Early Stage

Mid Stage

Late Stage

Phase Distribution222 total trials

Early Phase 1First-in-human

1(0.5%)

Phase 1Safety & dosage

138(62.2%)

Phase 2Efficacy & side effects

73(32.9%)

Phase 3Large-scale testing

5(2.3%)

N/ANon-phased studies

5(2.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

72.7%

141 of 194 finished

Non-Completion Rate

27.3%

53 ended early

Currently Active

trials recruiting

Total Trials

223

all time

Status Distribution

Active(25)

Completed(141)

Terminated(53)

Other(4)

Detailed Status

Completed141

Terminated42

Active, not recruiting16

Withdrawn11

Recruiting7

unknown4

Development Timeline

Analytics

Development Status

Total Trials

223

Active

Success Rate

77.0%

Most Advanced

Phase 3

Trials by Phase

Early Phase 11 (0.5%)

Phase 1138 (62.2%)

Phase 273 (32.9%)

Phase 35 (2.3%)

N/A5 (2.3%)

Trials by Status

active_not_recruiting167%

completed14163%

recruiting73%

terminated4219%

withdrawn115%

unknown42%

not_yet_recruiting21%

Recent Activity

23 active trials

Showing 5 of 223

active_not_recruitingphase_1

Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas

NCT00268385

recruitingphase_1

An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab

NCT03167437

active_not_recruitingphase_2

Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

NCT01522976

active_not_recruitingphase_1

Vorinostat, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma

NCT00972478

recruitingphase_2

Pediatric Precision Laboratory Advanced Neuroblastoma Therapy

NCT02559778

View all 223 trials

Clinical Trials (223)

Showing 20 of 223 trialsScroll for more

NCT00268385Phase 1

Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas

Active Not Recruiting

NCT03167437Phase 1

An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab

Recruiting

NCT01522976Phase 2

Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

Active Not Recruiting

NCT00972478Phase 1

Vorinostat, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma

Active Not Recruiting

NCT02559778Phase 2

Pediatric Precision Laboratory Advanced Neuroblastoma Therapy

Recruiting

NCT05848687Phase 1

TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II

Recruiting

NCT01281176Phase 1

High-Dose or Low-Dose Vorinostat in Combination With Carboplatin or Paclitaxel in Treating Patients With Advanced Solid Tumors

Active Not Recruiting

NCT04308330Phase 1

Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies

Recruiting

NCT01587352Phase 2

Vorinostat in Treating Patients With Metastatic Melanoma of the Eye

Active Not Recruiting

NCT00392353Phase 1

Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia

Active Not Recruiting

NCT00336063Phase 1

Vorinostat and Azacitidine in Treating Patients With Locally Recurrent or Metastatic Nasopharyngeal Cancer or Nasal Natural Killer T-Cell Lymphoma

Active Not Recruiting

NCT06995521Phase 2

Vorinostat for Graft-versus-host Disease (GVHD) Prevention in Non-Malignant Adolescent and Young Adults (AYA) Population

Not Yet Recruiting

NCT03742245Phase 1

Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer

Active Not Recruiting

NCT00616967Phase 2

Carboplatin and Nab-Paclitaxel With or Without Vorinostat in Treating Women With Newly Diagnosed Operable Breast Cancer

Active Not Recruiting

NCT00875056Phase 2

Study of Vorinostat (MK-0683) With Follicular Lymphoma (FL), Other Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL), or Mantle Cell Lymphoma (MCL) Participants (MK-0683-103)

Completed

NCT06145633Phase 2

Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer

Recruiting

NCT03842696Phase 1

Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation

Active Not Recruiting

NCT01087554Phase 1

Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer

Active Not Recruiting

NCT05317403Phase 1

Venetoclax to Augment Epigenetic Modification and Chemotherapy